Octopus Biosafety SA

As of December 31, 2024, Octopus Biosafety SA carries a market capitalization of 2.74M, placing it among publicly traded companies globally. Its enterprise value stands at 3.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, Octopus Biosafety SA has 14.78M shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 52.29, and the price-to-book ratio stands at -4.17.

These figures are as of December 31, 2024. The EV/Sales ratio of 62.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.26M versus a market cap of 2.74M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2024, Octopus Biosafety SA maintains a current ratio of 0.31, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -83.36, indicating conservative leverage, while an interest coverage ratio of -684.78 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -104.59, reflecting losses generated across the asset base. Inventory turnover of 19.43 indicates how many times Octopus Biosafety SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2024, Octopus Biosafety SA recorded an income tax benefit of -209,065.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -838,705.00 and -659,106.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Octopus Biosafety SA's stock has declined approximately 54.71% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 0.20.

Over the twelve months ended December 31, 2024, Octopus Biosafety SA generated 52,308.00 in revenue and converted that into -659,106.00 in net income, yielding earnings per share of -0.04. EBITDA reached -837,482.00, while operating income came in at -538,537.00.

As of December 31, 2024, Octopus Biosafety SA holds 22,872.00 in cash and equivalents against 546,838.00 in total debt, resulting in a net debt position of 523,966.00. Total book value stands at -655,967.00, with working capital of -675,206.00 providing operational flexibility.

Over the twelve months ended December 31, 2024, Octopus Biosafety SA posted a gross margin of -642.91, reflecting its pricing power and cost economics. The operating margin of -1,029.55 and net profit margin of -1,260.05 provide insight into operational efficiency.

Octopus Biosafety SA's most recent stock split took place on December 4, 2020 with a 203:255 split ratio.

As of December 31, 2024, Octopus Biosafety SA has an Altman Z-Score of -35.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.